Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.
致力於開發神經退行性疾病改良療法的生物技術公司Alterity Therapeutics（（澳大利亞證券交易所股票代碼：ATH，納斯達克股票代碼：ATH）（“Alterity” 或 “公司”）今天宣佈，獨立數據監測委員會（DMC）已完成對試驗數據的第三次審查，並建議按計劃繼續進行 ATH434-201 二期研究。ATH434-201 臨床試驗是一項針對早期多系統萎縮 (MSA) 患者的 ATH434 的隨機、雙盲、安慰劑對照研究，這是一種罕見的神經退行性疾病，沒有獲得批准的減緩或停止其進展的治療方法。
譯文內容由第三人軟體翻譯。